• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Elevation Pharmaceuticals

edit

Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients’ lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders – employees, investors, partners, and patients.

Milestones

edit

• 
  Elevation Pharmaceuticals added Bill Gerhart as President & CEO.
  Posted 1/21/10 at 8:26pm
• 
  Elevation Pharmaceuticals received $30M in Series B funding. (1/4/12)
  Posted 1/4/12 at 8:05pm via elevationpharma.com
• 
  Elevation Pharmaceuticals received $17M in Series A funding. (9/26/11)
  Posted 9/26/11 at 8:09pm via xconomy.com
• 
  Elevation Pharmaceuticals received $30M in Series A funding. (1/21/10)
  Posted 1/21/10 at 8:26pm via finsmes.com

Videos

Screenshots

edit

Above: Home Page
Uploaded: 1/22/10

Sources

1. Elevation Pharmaceuticals Raises $30M in Series A Financing (finsmes.com) [edit]
2. Elevation Pharma Pulls in $17M to Advance Lung Drug Trial (xconomy.com) [edit]
3. Elevation Pharmaceuticals Completes $30 Million Series B Financing to Advance Aerosol COPD Therapy (elevationpharma.com) [edit]